These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11926387)

  • 1. Visualisation and assessment of the protein synthesis rate of lung cancer using carbon-11 tyrosine and positron emission tomography.
    Pieterman R; Willemsen A; Appel M; Pruim J; Koëter G; Vaalburg W; Groen H
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):243-7. PubMed ID: 11926387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-1-11C-tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate.
    de Boer JR; Pruim J; van der Laan BF; Que TH; Willemsen AT; Albers FW; Vaalburg W
    J Nucl Med; 2003 Mar; 44(3):341-6. PubMed ID: 12620998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas.
    de Boer JR; van der Laan BF; Pruim J; Que TH; Burlage F; Krikke A; Willemsen AT; Tiebosch AT; Albers FW; Vaalburg W
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1182-7. PubMed ID: 12192563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy.
    Ceriani L; Giovanella L; Bandera M; Beghe B; Ortelli M; Roncari G
    Nucl Med Commun; 1997 Nov; 18(11):1087-97. PubMed ID: 9423210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
    van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
    J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas.
    Plaat B; Kole A; Mastik M; Hoekstra H; Molenaar W; Vaalburg W
    Eur J Nucl Med; 1999 Apr; 26(4):328-32. PubMed ID: 10199937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.
    Kole AC; Pruim J; Nieweg OE; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
    J Nucl Med; 1997 Feb; 38(2):191-5. PubMed ID: 9025733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of protein synthesis in the human brain using L-[1-11C]-leucine PET: incorporation of factors for large neutral amino acids in plasma and for amino acids recycled from tissue.
    Sundaram SK; Muzik O; Chugani DC; Mu F; Mangner TJ; Chugani HT
    J Nucl Med; 2006 Nov; 47(11):1787-95. PubMed ID: 17079811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma.
    de Boer JR; Pruim J; Albers FW; Burlage F; Vaalburg W; van der Laan BF
    J Nucl Med; 2004 Dec; 45(12):2052-7. PubMed ID: 15585481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience.
    de Jong IJ; Pruim J; Elsinga PH; Jongen MM; Mensink HJ; Vaalburg W
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1283-8. PubMed ID: 12271408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography.
    Miles KA; Griffiths MR; Keith CJ
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):22-8. PubMed ID: 16180030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
    Choi NC; Fischman AJ; Niemierko A; Ryu JS; Lynch T; Wain J; Wright C; Fidias P; Mathisen D
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1024-35. PubMed ID: 12419428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.